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Neuro-oncologists confront a paradox in the treatment of high grade gliomas. As these tumours do not
disseminate outside the central nervous system they might be considered the ideal localised tumours for
treatment with surgery and radiotherapy. This is the theory, but it has not been borne out in practice.
The results are poor: the median survival of patients treated with surgery alone is only 14 weeks.
Following radiotherapy it is prolonged to 40-50 weeks with only 15-25% of patients alive at 18 months
and few long-term survivors (Walker et al., 1979).
There has been no shortage of well conducted large multi-centre randomised trials. They have
identified age, performance status and tumour histology as the most important determinants of survival;
they have helped in discarding 'promising' but ineffective treatments and to formulate guidelines for
current management (Shapiro, 1986). None of the studies has provided a real chance of prolonged
survival for the individual patient, except the addition of adjuvant chemotherapy (nitrosoureas), which
marginally improves the results with a survival advantage of 9% at 1 year and 3% at 2 years (Stenning
et al., 1987), and this is of questionable clinical significance.
Why does the present treatment fail to eradicate high grade glioma? The unacceptable nature of
permanent neurological deficit makes it impossible to excise critical or large regions of normal brain. It
is similarly not acceptable to irradiate normal brain beyond radiation tolerance to doses that cause
damage to the central nervous system (CNS), which has little hope of recovery. Limited radiation
tolerance of the CNS coupled with relative radio-resistance of glial tumours (G.G. Steel et al.,
unpublished) results in a poor therapeutic ratio and ultimately failure of tumour control. Yet
radiotherapy remains the most effective treatment modality in high grade gliomas and it is reasonable to
exploit it further.
Modification of radiation response
Attempts at improving therapeutic ratio have addressed radiobiological theories in vogue. The use of
radiosensitisers (MRC Working Party, 1983) hyperbaric oxygen (Chang, 1977) and neutron beam
therapy (Catterall et al.. 1980, Duncan et al., 1986; Laramore et al., 1988) to overcome the presumed
problem of hypoxia have met with little success. The technical difficulties in the application of
hyperbaric oxygen and neutrons have meant that most of the studies have included small numbers of
patients and could be criticised because of their low discriminating power. However, they have not
shown a significant survival advantage and the likely magnitude of a potential difference would not
justify such inaccessible technology.
Radiobiological theory more recently turned to cell kinetic differences between brain tumour and
normal brain tissue. The high proliferation rate of high grade gliomas (Hoshino et al., 1980. 1985)
suggested that accelerated fractionation, which shortens the overall treatment time, may further inhibit
the regeneration of tumour cells. By giving more than one fraction per day tumour repopulation during
treatment is reduced with a potential for a better tumour control for a given dose level, providing there
is no increase in late normal tissue injury (Thames et al., 1983). The kinetics of repair of rat spinal cord,
which is used as the model of late injury of the central nervous system, is relatively slow (Ang et al.,
1984). Radiation repair is not complete within 6h and accelerated fractionation with short time interval
between fractions therefore carries the potential risk of increased late normal tissue damage.
Early studies have not demonstrated a survival advantage for accelerated radiotherapy (Douglas et
al., 1982; Payne et al., 1982; Keim et al., 1987). Nevertheless, treatment can be completed in 2-4 weeks
with little adverse effect and this avoids protracted 6-week therapy, which is often unacceptable in
patients with limited prognosis. The low toxicity demonstrated in these studies cannot be considered as
proof of safety of accelerated fractionation as the survival of the patients studied is often too short for
the full expression of late CNS injury.
Hyperfractionation, the use of small dose fractions in the same overall treatment time, exploits the
differences in repair capacity between tumour and late responding normal tissues. In CNS radiotherapy
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it may allow for a higher total dose and result in increased tumour cell kill. Small randomised studies of
hyperfractionation have yielded conflicting results (Fulton et al., 1984; Green et al., 1984; Packer et al.,
1987; Ludgate et al., 1988). Overall there is little survival advantage, although an optimum dose level
may not have been reached. Increasing the total dose using small doses per fraction is being tested
further (Freeman et al., 1988) but this will have to be done with caution as the actual sparing of late
tissue damage with gradual reduction of dose per fraction from 2 to 1 Gy is less than would be
predicted from radiobiological models (van der Schueren et al., 1988).
Halogenated pyrimidine analogues BUDR and IUDR are taken up in the DNA of cycling cells and
act as selective radiosensitisers for proliferating tissues (Kinsella et al., 1987). They have been
administered throughout the course of radiotherapy in glioma patients (Kinsella et al., 1988; Greenberg
et al., 1988) but a survival benefit with this approach is yet to be demonstrated. This will require large
randomised studies as the experimental enhancement ratio is relatively small and the tumour cell uptake
of these agents may not be adequate.
Inclreasing radiation dose
The major advance in neuro-oncology has come from stereotactic neurosurgical technology. More
accurate tumour definition with three-dimensional image reconstruction allows for precise biopsy and
tumour excision with computer-aided systems (Kelly, 1987). The techniques have also been adapted to
improve tumour localisation and for more accurate delivery of interstitial or external beam radio-
therapy. On theoretical grounds it should be possible to increase tumour dose with no influence on
normal tissue damage by reducing the volume of normal brain irradiated (Lyman, 1985). This is a
reasonable approach and it may improve results, but only if high grade gliomas are truly localised
tumours and if higher radiation dose would result in better tumour control.
The localised nature of glial tumours is a contentious issue, discussed fully in a recent review
(Halperin et al., 1988). The debate centres around the correlation between the apparent tumour margin
seen on CT scan (or other imaging procedure) and the histological evidence of tumour spread.
Hochberg & Pruitt (1980) reported that 81% of tumours recur within 2cm of the tumour margin. With
current histological techniques and three-dimensional reconstruction the tumour invasion beyond the CT
margin is more variable and exceeds 3cm in up to 13% of cases (Burger et al., 1988). Nevertheless,
tumour recurs locally in the majority of patients (Hochberg et al., 1980) and the main cause of death is
the progression of disease at the primary site with only 5-9% developing multiple lesions (Choucair et
al., 1986; Barnard et al., 1987). More accurate tumour localisation and more effective local treatment
may, therefore, cure a proportion of patients with truly circumscribed disease. If the current techniques
for detection of tumour cells underestimate tumour spread, better local treatment may prolong disease-
free survival with little effect on long-term survival as recurrences may occur further from the putative
tumour margin.
The grounds for optimism that increasing radiation dose may achieve better tumour control are based
on randomised studies of the BTSG (Walker et al., 1979). An improvement in median survival was
demonstrated with dose increased from 50 to 60 Gy, although there was no increase in the number of
long-term survivors with the higher dose of radiation. It is not clear if even higher doses would provide
additional benefit. Early phase II studies of small numbers of selected patients treated to doses up to
80 Gy suggested a prolongation of survival (Salazar et al., 1979) but a randomised RTOG study (Chang
et al., 1983) failed to show an improvement with a boost to a total tumour dose of 70Gy compared to
60Gy. Optimal therapeutic ratio with large volume irradiation and conventional fractionation is, probably,
reached at 55-60Gy. Pushing the dose to large target volumes beyond the conventional radiation
tolerance is unlikely to lead to improved results. This, however, may not hold for irradiation of small
target volumes.
The neuro-oncology world has been swept by a wave of enthusiasm for interstitial radiotherapy which
delivers high doses of radiation to small tumour volume. The doses of radiation used are well beyond
known radiation tolerance and this is a departure from standard radiotherapy practice in the CNS. The
aim is to induce cell kill without preservation of residual normal brain tissue at the tumour site, as it is
assumed that there is no important functional nervous tissue within the confines of tumour as seen on
CT scan. With high radiation doses there is likely to be some normal tissue damage, particularly at the
periphery of the tumour, and this may limit such technique to small volumes and to tumours within less
functionally important regions of the brain.
There are many publications describing interstitial radiotherapy techniques using either iodine-125 or
iridium-192 sources (e.g. Gutin et al., 1984; Findlay et al., 1985; Eddy et al., 1986; Salcman et al., 1986;
Ostertag, 1987; Mundinger, 1987) but few present interpretable results. A recent update of San
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reported a median survival of 86 weeks in patients with anaplastic astrocytoma and 53 weeks in patients
with glioblastoma multiforme. Tumour doses ranged from 50 to 120Gy (re-treatment) and were not
without complications. Thirty-five per cent of patients had to undergo post-implantation craniotomy,
usually for resection of necrotic tissue, and this group had a particularly favourable outcome in terms of
survival. The results have to be interpreted with caution. Patients were highly selected and an exhaustive
analysis by prognostic factors is not yet available. It is possible that re-operation alone is the effective
treatment as selected patients with recurrent astrocytoma have been reported to do well following
surgery without re-irradiation (Moser, 1988). Nevertheless, the reported interstitial radiotherapy
experience is as yet the best that has been achieved and should be tested in controlled prospective
studies.
Brachytherapy is an invasive technique within a province of a highly specialised neurosurgical centre.
A similar dose distribution may be achieved with stereotactic external beam radiotherapy. Small volume
focal radiation was initially delivered with a dedicated 'gamma unit' containing over 200 focused cobalt-
60 sources (for review see Leksell, 1987). More recently a number of centres have developed stereotactic
external beam radiotherapy with multiple noncoplanar arcs of rotation or simultaneous gantry and
couch movement ('dynamic radiotherapy') using a standard linear accelerator (Colombo et al., 1985;
Hartmann et al., 1985; Houdek et al., 1985; Greitz et al., 1986; Podgorsak et al., 1988; Lutz et al.,
1988). Single high-dose stereotactic irradiation (described as 'radiosurgery') has been used for the
treatment of arterio-venous malformations, but the technique is also suitable for radiotherapy of brain
tumours. With the development of relocatable fixation devices (Gill et al., 1989) it will be possible to
deliver fractionated focal irradiation on equipment available in most radiotherapy centres. Technical
progress is not necessarily clinical progress and any benefit will have to be proven in well designed
prospective studies.
Any attempt at improving results with more aggressive therapy must look not only at survival but
also at quality of life. Patients with brain tumours suffer from multiple functional disorders affecting
mobility, communication, cognitive function and personality. Quality of life measurements such as
Karnofsky scale are not adequate for assessing brain tumour patients and any future studies in the
treatment of CNS tumours should therefore include full evaluation of the patient's functional status.
Gloom about the current outcome of treatment of high grade gliomas may be justified but often leads
to despondency which is unlikely to benefit either present or future patients with brain tumours. While
we continue looking for new ways of controlling the aggressive proliferation of malignant glial tissue
there is scope for sharpening the existing tools. Radiotherapy is an effective treatment modality and
both new and existing technology can be developed further with a potential for improved results.
However, any survival advantage which may be gained from new treatment must be accompanied by
improved quality of life or the efforts will have been wasted.
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